BCYC (Bicycle Therapeutics) Float Percentage Of Total Shares Outstanding : 63.72% (As of Mar. 02, 2025)

View and export this data going back to 2019. Start your Free Trial

What is Bicycle Therapeutics Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Bicycle Therapeutics's float shares is 44.10 Mil. Bicycle Therapeutics's total shares outstanding is 69.20 Mil. Bicycle Therapeutics's float percentage of total shares outstanding is 63.72%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Bicycle Therapeutics's Insider Ownership is 2.08%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Bicycle Therapeutics's Institutional Ownership is 60.69%.

Bicycle Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Bicycle Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	44.10	/	69.20
	=	63.72%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bicycle Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bicycle Therapeutics PLC (NAS:BCYC) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

50BA:Germany

Address

Granta Park, Great Abington, Blocks A and B, Portway Building, Cambridge, GBR, CB21 6GS

Website

https://www.bicycletherapeutics.com

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.

Executives

Travis Alvin Thompson	officer: Chief Accounting Officer	C/O BICYCLE THERAPEUTICS PLC, BLOCKS A & B, PORTWAY BUILDING, CAMBRIDGE X0 CB21 6GS
Nigel Crockett	officer: Chief Business Officer	C/O BICYCLE THERAPEUTICS PLC, B900, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Alistair Milnes	officer: Chief Operating Officer	C/O BICYCLE THERAPEUTICS PLC, B900, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Kevin Lee	director, officer: Chief Executive Officer	C/O BICYCLE THERAPEUTICS LIMITED, B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB223AT
Michael Skynner	officer: Chief Operating Officer	C/O BICYCLE THERAPEUTICS LIMITED, B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB223AT
Alethia Young	officer: Chief Financial Officer	C/O GRAPHITE BIO, INC., 201 HASKINS WAY, SUITE 210, SOUTH SAN FRANCISCO CA 94080
Santiago Arroyo	officer: Chief Development Officer	C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Nicholas Keen	officer: Chief Scientific Officer	C/O BICYCLE THEAPEUTICS LIMITED, B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Lee Kalowski	officer: President and CFO	C/O TOKAI PHARMACEUTICALS, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Dominic Smethurst	officer: Chief Medical Officer	C/O BICYCLE THERAPEUTICS PLC, B900, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Pierre Legault	director	P.O. BOX 1028, C/O STONE MANAGEMENT LLC, BERWYNE PA 19312
Kate Bingham	director	1365 MAIN STREET, WALTHAM MA 02451
Jose-carlos Gutierrez-ramos	director	C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Plc Glaxosmithkline	director, 10 percent owner	980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS
Veronica Gh Jordan	director	C/O ALBANY MOLECULAR RESEARCH, INC., 26 CORPORATE CIRCLE, ALBANY NY 12212-5098